LncRNA FGD5-AS1 accelerates cell proliferation in pancreatic cancer by regulating miR-520a-3p/KIAA1522 axis

References

• Ilic M, Ilic I. Epidemiology of pancreatic cancer. World Journal of Gastroenterology. 2016;22(44):9694–9705. doi:10.3748/wjg.v22.i44.9694.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.21442.
   PubMed Web of Science ®Google Scholar
• Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C, Sasor A, Borg D, Bauden M, Andersson R. Pancreatic cancer: yesterday, today and tomorrow. Future Oncology (London, England). 2016;12(16):1929–1946. doi:10.2217/fon-2016-0010.
   PubMed Web of Science ®Google Scholar
• Goral V. Pancreatic cancer: pathogenesis and diagnosis. Asian Pacific Journal of Cancer Prevention: APJCP. 2015;16(14):5619–5624. doi:10.7314/APJCP.2015.16.14.5619.
   PubMedGoogle Scholar
• Jathar S, Kumar V, Srivastava J, Tripathi V. Technological developments in lncRNA biology. Adv Exp Med Biol. 2017;1008:283–323.
   PubMed Web of Science ®Google Scholar
• Chen X, Sun Y, Cai R, Wang G, Shu X, Pang W. Long noncoding RNA: multiple players in gene expression. BMB Rep. 2018;51(6):280–289. doi:10.5483/BMBRep.2018.51.6.025.
   PubMed Web of Science ®Google Scholar
• Dey BK, Mueller AC, Dutta A. Long non-coding RNAs as emerging regulators of differentiation, development, and disease. Transcription. 2014;5(4):e944014. doi:10.4161/21541272.2014.944014.
   PubMedGoogle Scholar
• Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965–3981. doi:10.1158/0008-5472.CAN-16-2634.
   PubMed Web of Science ®Google Scholar
• Gao H, Gong N, Ma Z, Miao X, Chen J, Cao Y, Zhang G. LncRNA ZEB2-AS1 promotes pancreatic cancer cell growth and invasion through regulating the miR-204/HMGB1 axis. Int J Biol Macromol. 2018;116:545–551. doi:10.1016/j.ijbiomac.2018.05.044.
   PubMed Web of Science ®Google Scholar
• Zhao L, Sun H, Kong H, Chen Z, Chen B, Zhou M. The Lncrna-TUG1/EZH2 axis promotes pancreatic cancer cell proliferation, migration and EMT phenotype formation through sponging Mir-382. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology. 2017;42(6):2145–2158. doi:10.1159/000479990.
   PubMedGoogle Scholar
• Li D, Jiang X, Zhang X, Cao G, Wang D, Chen Z. Long noncoding RNA FGD5-AS1 promotes colorectal cancer cell proliferation, migration, and invasion through upregulating CDCA7 via sponging miR-302e. In Vitro Cell Dev Biol Anim. 2019;55(8):577–585. doi:10.1007/s11626-019-00376-x.
   PubMed Web of Science ®Google Scholar
• Fan Y, Li H, Yu Z, Dong W, Cui X, Ma J, Li S. Long non-coding RNA FGD5-AS1 promotes non-small cell lung cancer cell proliferation through sponging hsa-miR-107 to up-regulate FGFRL1. Biosci Rep. 2020;40(1):BSR20193309.
   Google Scholar
• Qadir MI, Faheem A. miRNA: a diagnostic and therapeutic tool for pancreatic cancer. Crit Rev Eukaryot Gene Expr. 2017;27(3):197–204. doi:10.1615/CritRevEukaryotGeneExpr.2017019494.
   PubMed Web of Science ®Google Scholar
• Mishra S, Yadav T, Rani V. Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol. 2016;98:12–23. doi:10.1016/j.critrevonc.2015.10.003.
   PubMed Web of Science ®Google Scholar
• Vishnoi A, Rani S. MiRNA biogenesis and regulation of diseases: an overview. Methods in Molecular Biology (Clifton, NJ). 2017;1509:1–10.
   PubMedGoogle Scholar
• Zhang Z, Che X, Yang N, Bai Z, Wu Y, Zhao L, Pei H. miR-135b-5p promotes migration, invasion and EMT of pancreatic cancer cells by targeting NR3C2. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2017;96:1341–1348. doi:10.1016/j.biopha.2017.11.074.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang B, Ren H, Chen W. miR-9-5p inhibits pancreatic cancer cell proliferation, invasion and glutamine metabolism by targeting GOT1. Biochem Biophys Res Commun. 2019;509(1):241–248. doi:10.1016/j.bbrc.2018.12.114.
   PubMed Web of Science ®Google Scholar
• Yan D, Liu W, Liu Y, Luo M. LINC00261 suppresses human colon cancer progression via sponging miR-324-3p and inactivating the Wnt/β-catenin pathway. J Cell Physiol. 2019;234(12):22648–22656. doi:10.1002/jcp.28831.
   PubMed Web of Science ®Google Scholar
• Ji N, Wang Y, Bao G, Yan J, Ji S. LncRNA SNHG14 promotes the progression of cervical cancer by regulating miR-206/YWHAZ. Pathol Res Pract. 2019;215(4):668–675. doi:10.1016/j.prp.2018.12.026.
   PubMed Web of Science ®Google Scholar
• Luan X, Wang Y. LncRNA XLOC_006390 facilitates cervical cancer tumorigenesis and metastasis as a ceRNA against miR-331-3p and miR-338-3p. J Gynecol Oncol. 2018;29(6):e95. doi:10.3802/jgo.2018.29.e95.
   PubMed Web of Science ®Google Scholar
• Wang H, Huo X, Yang XR, He J, Cheng L, Wang N, Deng X, Jin H, Wang N, Wang C. STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Mol Cancer. 2017;16(1):136. doi:10.1186/s12943-017-0680-1.
   PubMed Web of Science ®Google Scholar
• Zhang G, Li S, Lu J, Ge Y, Wang Q, Ma G, Zhao Q, Wu D, Gong W, Du M. LncRNA MT1JP functions as a ceRNA in regulating FBXW7 through competitively binding to miR-92a-3p in gastric cancer. Mol Cancer. 2018;17(1):87. doi:10.1186/s12943-018-0829-6.
   PubMed Web of Science ®Google Scholar
• Qi X, Zhang DH, Wu N, Xiao JH, Wang X, Ma W. ceRNA in cancer: possible functions and clinical implications. J Med Genet. 2015;52(10):710–718. doi:10.1136/jmedgenet-2015-103334.
   PubMed Web of Science ®Google Scholar
• Sen R, Ghosal S, Das S, Balti S, Chakrabarti J. Competing endogenous RNA: the key to posttranscriptional regulation. TheScientificWorldJournal. 2014;2014:896206. doi:10.1155/2014/896206.
   PubMedGoogle Scholar
• Li J, Wei J, Mei Z, Yin Y, Li Y, Lu M, Jin S. Suppressing role of miR-520a-3p in breast cancer through CCND1 and CD44. Am J Transl Res. 2017;9(1):146–154.
   PubMed Web of Science ®Google Scholar
• Lv X, Li CY, Han P, Xu XY. MicroRNA-520a-3p inhibits cell growth and metastasis of non-small cell lung cancer through PI3K/AKT/mTOR signaling pathway. Eur Rev Med Pharmacol Sci. 2018;22(8):2321–2327. doi:10.26355/eurrev_201804_14822.
   PubMed Web of Science ®Google Scholar
• Bi CL, Zhang YQ, Li B, Guo M, Fu YL. MicroRNA-520a-3p suppresses epithelial-mesenchymal transition, invasion, and migration of papillary thyroid carcinoma cells via the JAK1-mediated JAK/STAT signaling pathway. J Cell Physiol. 2019;234:4054–4067. doi:10.1002/jcp.27199.
   PubMedGoogle Scholar
• Xie ZH, Yu J, Shang L, Zhu YQ, Hao JJ, Cai Y, Xu X, Zhang Y, Wang MR. KIAA1522 overexpression promotes tumorigenicity and metastasis of esophageal cancer cells through potentiating the ERK activity. Onco Targets Ther. 2017;10:3743–3754. doi:10.2147/OTT.S142610.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang Y, Fan H, Zhang Z, Li N. miR-125b-5p inhibits breast cancer cell proliferation, migration and invasion by targeting KIAA1522. Biochem Biophys Res Commun. 2018;504(1):277–282. doi:10.1016/j.bbrc.2018.08.172.
   PubMed Web of Science ®Google Scholar
• Liu YZ, Yang H, Cao J, Jiang YY, Hao JJ, Xu X, Cai Y, Wang MR. KIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer. Sci Rep. 2016;6(1):24786. doi:10.1038/srep24786.
   PubMedGoogle Scholar